Finerenone Slows Progression in CVD, Reduces CV Events, Study Says

October 23, 2020 10:00pm

Finerenone slowed chronic kidney disease progression by 18% and cut cardiovascular events by 14%, according to phase 3 trial results.

Dr Guofen Yan On the Mechanism Behind Racial Disparities in ESKD Incidence
Dr Lametra Scott Discusses Cost, Formulary Guidance in Managing Sickle Cell Disease
Prescribing Patterns for Second-Line Treatment of Rheumatoid Arthritis
Areas to Watch in Specialty Drug Pipeline Include Cancer, Orphan Drugs

Dr Rajiv Agarwal Discusses Finerenone, Results of FIDELIO-DKD

October 23, 2020

The investigational drug finerenone met its primary endpoint in FIDELIO-DKD of slowing progression of chronic kidney disease (CKD) in patients with type 2 diabetes and CKD, said Rajiv Agarwal, MD, MS, FASN, a professor of medicine at Indiana University School of Medicine and a staff physician at the Veterans Affairs Medical Center in Indianapolis, Indiana.

Understanding the Complicated Patchwork of State Drug Pricing Reform Legislation

October 23, 2020

The pressure on state budgets exerted by new approvals of costly therapeutics has led many states to implement legislation aimed at regulating drug prices, but the success of these efforts is not uniform across the nation.